siRNA as a new drug: intellectual property

Bibliography

• CAPLEN NJ: Gene therapy progress and prospects. Downregulating gene expression: the impact of RNA interference. Gene Ther. (2004) 11:1241–1248.
   Google Scholar
• DOWNWARD J: RNA interference. Br. Med. J. (2004) 328:1245–1248.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY MK: RNA interference: historical overview and significance. Methods Mol. Biol. (2004) 265:3–21.
   PubMedGoogle Scholar
• MEDEMA RH: Optimizing RNA interference for application in mammalian cells. Biochem. J. (2004) 380:593–603.
   Google Scholar
• DUXBURY MS, WHANG EE: RNA interference: a practical approach. Surg Res. (2004) 117:339–344.
   PubMed Web of Science ®Google Scholar
• KAWASAKI H, TAIRA K: Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Nature (2004) 431:211–217.
   PubMed Web of Science ®Google Scholar
• MORRIS KV, CHAN SW, JACOBSEN SE, LOONEY DJ: Small interfering RNA-induced transcriptional gene silencing in human cells. Science (2004) 305:1289–1292.
   PubMed Web of Science ®Google Scholar
• PAL-BHADRA M, BHADRA U, BIRCHLER JA: RNAi related mechanisms affect both transcriptional and post-transcriptional transgene silencing in Drosophila. Mol. Cell. (2002) 9:315–327.
   PubMed Web of Science ®Google Scholar
• ELBASHIR SM, HARBORTH J, LENDECKEL W, YALCIN A, WEBER K, TUSCHL T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 411:494–498.
   PubMed Web of Science ®Google Scholar
• KUMAR M, CARMICHAEL GG: Antisense RNA: function and fate of duplex RNA in cells of higher eulcaryotes. Microbiol Mol. Biol. Rev. (1998) 62:1415–1434.
   PubMed Web of Science ®Google Scholar
• JACOBS BL, LANGLAND JO: When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA. Virology (1996) 219:339–349.
   PubMed Web of Science ®Google Scholar
• ELBASHIR SM, LENDECKEL W, TUSCHL T: RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. (2001) 15:188–200.
   PubMed Web of Science ®Google Scholar
• MEISTER G, LANDTHALER M, PATKANIOWSKA A, DORSETT Y, TENG G, TUSCHL T: Human Argonaute-2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol. Cell. (2004) 15:185–197.
   PubMed Web of Science ®Google Scholar
• FIRE A: RNA-triggered gene silencing. Trends Genet. (1999) 15:358–363.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY MK, XU S, FIRE A: RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegans. Proc. Natl Acad. Sci. USA (1998) 95:15502–15507.
   PubMed Web of Science ®Google Scholar
• TIMMONS L, FIRE k Specific interference by ingested dsRNA. Nature (1998) 395:854–857.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY MK, FIRE k Double-stranded RNA as a mediator in sequence-specific genetic silencing and suppression. Trends Trends Genet. (1998) 14:255–258.
   PubMed Web of Science ®Google Scholar
• FIRE A, XU S, MONTGOMERY MK, KOSTAS SA, DRIVER SE, MELLO CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 391:806–811.
   PubMed Web of Science ®Google Scholar
• SIJEN T, FLEENOR J, SIMMER F et al.: On the role of RNA amplification in dsRNA-triggered gene silencing. Cell (2001) 107:465–476.
   PubMed Web of Science ®Google Scholar
• NISHIKURA K: A short primer on RNAi: RNA-directed RNA polymerase acts as a key catalyst. Cell (2001) 107:415–418.
   PubMed Web of Science ®Google Scholar
• BALLEW NL: Benitec Ltd gene silencing from down under. Chem. Biol (2004) 11:285–286.
   Google Scholar
• LI YX, FARRELL MJ, LIU R, MOHANTY N, KIRBY ML: Double-stranded RNA injection produces null phenotypes in zebrafish. Dev. Biol. (2000) 217:394–405.
   PubMed Web of Science ®Google Scholar
• WARGELIUS A, ELLINGSEN S, FJOSE A: Double-stranded RNA induces specific developmental defects in zebrafish embryos. Biochem. Biophys. Res. Commun. (1999) 263:156–161.
   PubMed Web of Science ®Google Scholar
• STEIN P, SVOBODA P, SCHULTZ RM: Transgenic RNAi in mouse oocytes: a simple and fast approach to study gene function. Dev. Biol. (2003) 256:187–93.
   PubMed Web of Science ®Google Scholar
• WIANNY F, ZERNICKA-GOETZ M; Specific interference with gene function by double-stranded RNA in early mouse development. Nat. Cell Biol. (2000) 2:70–75.
   PubMed Web of Science ®Google Scholar
• HAMMOND SM, BOETTCHER S, CAUDY AA, KOBAYASHI R, HANNON GJ: Argonaute2, a link between genetic and biochemical analyses of RNAi. Science (2001) 293:1146–1150.
   PubMed Web of Science ®Google Scholar
• HAMMOND SM, GAUDY AA, HANNON GJ: Post-transcriptional gene silencing by double-stranded RNA. Nat. Rev. Genet. (2001) 2:110–119.
   PubMed Web of Science ®Google Scholar
• BERNSTEIN E, GAUDY AA, HAMMOND SM, HANNON GJ; Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature. (2001) 409:363–366.
   PubMed Web of Science ®Google Scholar
• HAMMOND SM, BERNSTEIN E, BEACH D, HANNON GJ: An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature (2000) 404:293–296.
   PubMed Web of Science ®Google Scholar
• XU Y, LINDE A, LARSSON 0 et al.: Functional comparison of single- and double-stranded siRNAs in mammalian cells. Biochem. Biophys. Res. Commun. (2004) 316:680–687.
   Google Scholar
• HOLEN T, AIVIARZGUIOUI M, BABAIE E, PRYDZ H: Similar behaviour of single-strand and double-strand siRNAs suggests they act through a common RNAi pathway. Nucleic Acids Res. (2003) 31:2401–2407.
   PubMed Web of Science ®Google Scholar
• PANNIER AK, SHEA LD: Controlled release systems for DNA delivery. Mo/. Ther. (2004) 10:19–26.
   PubMed Web of Science ®Google Scholar
• CROOKE ST: Antisense strategies. Curr. Mol Med. (2004) 4:465–487.
   PubMed Web of Science ®Google Scholar
• JEPSEN JS, SORENSEN MD, WENGEL J: Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology. Oligonucleotides (2004) 14:130–146.
   PubMed Web of Science ®Google Scholar
• LYSIK MA, WU-PONG S: Innovations in oligonucleotide drug delivery. J. Pharm. Sci. (2003) 92:1559–1573.
   PubMed Web of Science ®Google Scholar
• KURRECK J: Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. (2003) 270:1628–1644.
   Google Scholar
• GAMBARI R: Peptide-nucleic acids (PNAs): a tool for the development of gene expression modifiers. Curr. Pharm. Des. (2001) 7:1839–1862.
   PubMed Web of Science ®Google Scholar
• LAMBERT G, FATTAL E, COUVREUR P: Nanoparticulate systems for the delivery of antisense oligonucleotides. Adv. Drug Deliv. Rev. (2001) 47:99–112.
   PubMed Web of Science ®Google Scholar
• YUEN AR, SIKIC BI: Clinical studies of antisense therapy in cancer. Front Biosci. (2000) 5:D588–D5893.
   Google Scholar
• AGRAWAL S, ZHAO Q: Antisense therapeutics. Curr. Opin. Chem. Biol. (1998) 2:519–28.
   PubMed Web of Science ®Google Scholar
• HARBORTH J, ELBASHIR SM, VANDENBURGH K et al.: Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev. (2003) 13:83–105.
   PubMedGoogle Scholar
• AOKI Y, CIOCA DP, OIDAIRA H, KAIVIIYA J, KIYOSAWA K: RNA interference may be more potent than antisense RNA in human cancer cell lines. Clin. Exp. PharmacoL Physiol (2003) 30:96–102.
   PubMed Web of Science ®Google Scholar
• XU Y, ZHANG HY, THORMEYER D et al.: Effective small interfering RNAs and phosphorothioate antisense DNAs have different preferences for target sites in the luciferase mRNAs. Biochem. Biophys. Res. Commun. (2003) 306:712–717.
   PubMed Web of Science ®Google Scholar
• AMARZGUIOUI M, HOLEN T, BABAIE E, PRYDZ H: Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. (2003) 31:589–595.
   PubMed Web of Science ®Google Scholar
• HAIVIADA M, OHTSUKA T, KAWAIDA R et al.: Effects on RNA interference in gene expression (RNAi) in cultured mammalian cells of mismatches and the introduction of chemical modifications at the 3'-ends of siRNAs. Antisense Nucleic Acid Drug Dev. (2002) 12:301–309.
   Google Scholar
• CZAUDERNA F, FECHTNER M, DAMES S et al.: Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. (2003) 31:2705–2716.
   PubMed Web of Science ®Google Scholar
• LAYZER JM, MCCAFFREY AP, TANNER AK, HUANG Z, KAY MA, SULLENGER BA: In vivo activity of nuclease-resistant siRNAs. RNA (2004) 10:766–71.
   PubMed Web of Science ®Google Scholar
• HOLEN T, AIVIARZGUIOUI M, BABAIE E, PRYDZ H: Similar behaviour of single-strand and double-strand siRNAs suggests they act through a common RNAi pathway. Nucleic Acids Res. (2003) 31:2401–2407.
   PubMed Web of Science ®Google Scholar
• CHIU YL, RANA TM: siRNA function in RNAi: a chemical modification analysis. RNA. (2003) 9:1034–1048.
   PubMed Web of Science ®Google Scholar
• YUAN B, LATEK R, HOSSBACH M, TUSCHL T, LEWITTER F: siRNA Selection server: an automated siRNA oligonucleotide prediction server. Nucleic Acids Res. (2004) 32:W130–W134.
   Google Scholar
• AIVIARZGUIOUI M, PRYDZ H: An algorithm for selection of functional siRNA sequences. Biochem. Biophys. Res. Commun. (2004) 316:1050–1058.
   Google Scholar
• LORENZ C, HADWIGER P, JOHN M, VORNLOCHER HP, UNVERZAGT C: Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg. Med. Chem. Lett. (2004) 14:4975–4977.
   PubMed Web of Science ®Google Scholar
• SOUTSCHEK J, AKINC A. BRAMLAGE B et al.: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 432:173–8.
   Google Scholar
• DORSETT Y, TUSCHL T: siRNAs: applications in functional genomics and potential as therapeutics. Nat. Rev. Drug Discov. (2004) 3:318–29.
   PubMed Web of Science ®Google Scholar
• SCHIFFELERS RM, WOODLE MC, SCARIA P: Pharmaceutical prospects for RNA interference. Pharm. Res. (2004) 21:1–7.
   PubMed Web of Science ®Google Scholar
• STEVENSON M: Therapeutic potential of RNA interference. N Engl. J. Med. (2004) 351:1772–1777.
   PubMed Web of Science ®Google Scholar
• VERMA NK, DEY CS: RNA-mediated gene silencing: mechanisms and its therapeutic applications. J. Clin. Pharm. Ther. (2004) 29:395–404.
   PubMed Web of Science ®Google Scholar
• SCHERER L, ROSSI JJ: Recent applications of RNAi in mammalian systems. Curr. Pharm. Biotechnol (2004) 5:355–560.
   Google Scholar
• BRAASCH DA. PAROO Z, CONSTANTINESCU A et al: Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg. Med. Chem Lett. (2004) 14:1139–1143.
   PubMed Web of Science ®Google Scholar
• SONG E, LEE SK, WANG J et al.: RNA interference targeting Fas protects mice from fitlminant hepatitis. Nat. Med. (2003) 9:347–351.
   PubMed Web of Science ®Google Scholar
• HAMAR P, SONG E, KOKENY G, CHEN A, OUYANG N, LIEBERMAN J: Small interfering RNA targeting Fas protects mice against renal ischaemia-reperfusion injury. Proc. Nail. Acad. Sci. USA (2004) 101:14883–14888.
   PubMed Web of Science ®Google Scholar
• GILADI H, KETZINEL-GILAD M, RIVKIN L, FELIG Y, NUSSBAUM 0, GALUN E: Small interfering RNA inhibits hepatitis B virus replication in mice. MoL Ther. (2003) 8:769–776.
   PubMed Web of Science ®Google Scholar
• CONTRERAS JL, VILATOBA M, ECKSTEIN C, BILBAO G, ANTHONY THOMPSON J, ECKHOFF DE: Caspase-8 and caspase-3 small interfering RNA decreases ischaemia/reperfitsion injury to the liver in mice. Surgery (2004) 136:390–400.
   PubMed Web of Science ®Google Scholar
• HAGSTROM JE, HEGGE J, ZHANG G et al.: A facile nonviral method for delivering genes and siRNAs to skeletal muscle of mammalian limbs. Md. Ther. (2004) 10:386–398.
   PubMed Web of Science ®Google Scholar
• CHAE SS, PAIK JH, FURNEAUX H, HLA T: Requirement for sphingosine 1-phosphate receptor-1 in tumour angiogenesis demonstrated by in vivo RNA interference. J. Clin. Invest. (2004) 114:1082–1089.
   PubMed Web of Science ®Google Scholar
• NAKAMURA H, SIDDIQUI SS, SHEN X et al.: RNA interference targeting transforming growth factor-I3 Type II receptor suppresses ocular inflammation and fibrosis. MoL Vis. (2004) 10:703–711.
   PubMed Web of Science ®Google Scholar
• MINAKUCHI Y, TAKESHITA F, KOSAKA N et al.: Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res. (2004) 32:e109
   PubMed Web of Science ®Google Scholar
• HASSANI Z, LEMKINE GF, ERBACHER P et al. Lipid-mediated siRNA delivery downregulates exogenous gene expression in the mouse brain at picomolar levels. J. Gene Med. (2004) [Epub ahead of print].
   Google Scholar
• SORENSEN DR, LEIRDAL M, SIOUD M: Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J. Mot Bid. (2003) 327:761–766.
   PubMed Web of Science ®Google Scholar
• GE Q, FILIP L, BAI A, NGUYEN T, EISEN HN, CHEN J: Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc. Natl Acad. Sci. USA (2004) 101:8676–8681.
   PubMed Web of Science ®Google Scholar
• KIM B, TANG Q, BISWAS PS et al: Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor-pathway genes; therapeutic strategy for herpetic stromal keratitis. Am. J. PathoL (2004) 165:2177–2185.
   PubMed Web of Science ®Google Scholar
• SCHIFFELERS RM, ANSARI A, ZHOU Q et al.: Cancer siRNA therapy by tumour selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. (2004) 32:e149.
   PubMed Web of Science ®Google Scholar
• TOMANIN R, SCARPA M: Why do we need new gene therapy viral vectors? Characteristics, limitations and future perspectives of viral vector transduction. Curr. Gene Ther. (2004) 4:357–372.
   PubMed Web of Science ®Google Scholar
• WALTHER W, STEIN U: Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs (2000) 60:249–71.
   PubMed Web of Science ®Google Scholar
• WILSON DR: Viral-mediated gene transfer for cancer treatment. Curr. Pharm. Biotechnol. (2002) 3:151–164.
   PubMedGoogle Scholar
• DOBBELSTEIN M: Viruses in therapy - royal road or dead end? Virus Res. (2003) 92:219–221.
   Google Scholar
• XIA H, MAO Q, PAULSON HL, DAVIDSON BL: siRNA-mediated gene silencing in vitro and in vivo. Nat . Biotechnol (2002) 20:1006–1010
   PubMed Web of Science ®Google Scholar
• XIA H, MAO Q, ELIASON SL ell.: RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat. Med. (2004) 10:816–820.
   Google Scholar
• BAIN JR, SCHISLER JC, TAKEUCHI K,NEWGARD CB, BECKER TC: An adenovirus vector for efficient RNA interference-mediated suppression of target genes in insulinoma cells and pancreatic islets of Langerhans. Diabetes (2004) 53:2190–2194.
   PubMed Web of Science ®Google Scholar
• DUXBURY MS, ITO H, BENOIT E, ZINNER MJ, ASHLEY SW, WHANG EE: Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer. Surgery (2004) 136:261–269.
   Google Scholar
• MORRIS KV, ROSSI JJ: Anti-HIV-1 geneexpressing lentiviral vectors as an adjunctive therapy for HIV-1 infection. Curr. HIV Res. (2004) 2:185–91.
   Google Scholar
• LEE MT, COBURN GA, MCCLURE MO, CULLEN BR: Inhibition of human immunodeficiency virus Type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. J. Virol. (2003) 77:11964–11972.
   PubMed Web of Science ®Google Scholar
• TOMAR RS, MATTA H, CHAUDHARY PM: Use of adeno-associated viral vector for delivery of small interfering RNA. Oncogene (2003) 22(361:5712–5715.
   Google Scholar
• SIMEONI F, MORRIS MC, HEITZ F, DI VITA G: Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res. (2003) 31:2717–2724.
   PubMed Web of Science ®Google Scholar
• BRUGIDOU J, LEGRAND C, MERY J,RABIE A: The retro-inverso form of a homeobox-derived short peptide is rapidly internalised by cultured neurons: a new basis for an efficient intracellular delivery system. Biochem. Biophys. Res. Commun. (1995) 214:685–693.
   Google Scholar